ABOUT IMMUNOMIC THERAPEUTICS, INC.

At a moment in which nucleic acid vaccines are seeing a resurgence, Immunomic Therapeutics has developed a cutting-edge technology for DNA vaccination. The Company is commercializing LAMP-Vax, a breakthrough immunomodulation platform that has the potential to transform the rapidly growing allergy and cancer immunotherapy markets.

ITI has already executed three commercial partnerships - two with Astellas Pharma and one with Geron/Asterias. The Company believes these partnerships provide important validation of its scientific platform and partnering strategy. Initial license payments received exceed $300 million and pending milestone payments exceed $55 million. Additionally, ITI will receive double-digit royalties on allergy products, a market with multi-billion-dollar potential. ITI achieved this agreement while retaining the rights to the LAMP-Vax platform for other applications, including cancer immunotherapy.

ITI'S MISSION

The mission of Immunomic Therapeutics is to pioneer vaccines that transform lives.

ITI’S VISION

ITI's vision is that by 2025, it will have regulatory approved products in pollen allergy, food allergy, cancer and animal health.
Immunomic Team